Cassava Sciences Inc reports results for the quarter ended in December - Earnings Summary

Filana Therapeutics

28/02/2023 14:54

* Cassava Sciences Inc  SAVA.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was for a
loss of 56 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cassava Sciences Inc's reported EPS for the quarter was a
loss
of 47 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cassava Sciences Inc shares had fallen by 16.1% this
quarter.
    * The company reported a quarterly loss of $19.13 million.
    * Wall Street's median 12-month price target for Cassava
Sciences
Inc is $100.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 02:54 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.56          -0.47          Beat
 Sep. 30 2022      -0.48          -0.51          Missed
 Jun. 30 2022      -0.43          -0.48          Missed
 Mar. 31 2022      -0.41          -0.44          Missed